The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10750 malaria professionals are enjoying the free benefits of MalariaWorld today

proarrhythmia

Applying the CiPA Approach to Evaluate Cardiac Proarrhythmia Risk of some Antimalarials Used Off-label in the First Wave of COVID-19

February 25, 2021 - 09:44 -- Open Access
Author(s): 
Delaunois A, Abernathy M, Valentin JP, et al.
Reference: 
Clin Transl Sci. 2021 Feb 23

We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine-mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, drugs repurposed during the first wave of COVID-19. Each drug or drug combination was tested in patch clamp assays on 7 cardiac ion channels, in in silico models of human ventricular electrophysiology (Virtual Assay® ) using control (healthy) or high-risk cell populations, and in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes.

NOT Open Access | Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia

July 27, 2020 - 12:13 -- NOT Open Access
Author(s): 
Stremmel C, Kellnar A, Massberg S, Kääb S
Reference: 
J Cardiovasc Pharmacol Ther. 2020 Jul 23:1074248420935740

In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection.

Subscribe to RSS - proarrhythmia